

- **Emerging contaminants (ECs)** are compounds present in the environment for which there is a lack of chemical information but that are suspected to be harmful for humans and wildlife. Thus, there is an urgent need to identify and establish a set of **representative biomarkers** to assess the human exposure to ECs.
- **Human urine is a complex matrix**, most of the **ECs are present at trace levels (ng/mL)** and many types of contaminants are metabolized through different pathways and excreted via the urine as **metabolites**.
- **Non-target screening analysis** of human urine samples by high resolution mass-spectrometry is able to provide an **overview of the presence of ECs**. Since there are **no harmonized methods**, the obtained **results among different labs are not comparable neither reproducible**.
- The development of **reliable and comparable non-target/suspect screening workflows requires a complete set of QA/QC measures** in each single step of the workflow.
- **Quality assurance (QA)** is a set of activities or procedures which are adopted in a laboratory to ensure that all quality requirements will be fulfilled.
- **Quality control (QC)** refers to operational techniques and activities that are used to fulfil requirements for quality.


A universal QA/QC framework has been developed and applied to non-target screening analysis of human urine samples by LC-QTOFMS

SAMPLE TREATMENT

- Urine contents salts, proteins and phospholipids that cause matrix-effects during the LC-QTOFMS analysis.
- Sample treatment must maintain a balance between maximal compound extraction and minimal matrix-effect.


- 1 Background contamination**
 - ❖ Limited use of plastic material
 - ❖ High quality of solvents
 - ❖ Baked glass labware
- 2 MIX Isotopic labelled IS**
 - ❖ Wide range of polarities
 - ❖ Expected families of compounds
 - ❖ Endogenous compounds
 - ❖ Parent + Metabolites

- 3 Optimization & Pre-validation method**
 - ➔ Pooled-urine sample
 - ➔ MIX IS
 - Selectivity
 - Extraction efficiency
 - Universality
 - Time
 - Cost




LIQUID CHROMATOGRAPHY

- 1 MIX-IS**
 - ❖ Selection of mobile phase composition based on peak intensity, adducts and shape
 - ❖ Maximum resolution but keeping a soft chromatography gradient
 - ❖ Check if retention time shifts inter- & intra-worklist exist
 - ❖ Minimum volume of injection to avoid detector saturation and bad peak shapes
 - ❖ Check if carry-over exists
 - ❖ Check if overlapping of injections exists
 - ❖ Test of the analytical column for background contamination



- 2 Visual inspection**
 - ❖ Pressure profile
 - ❖ TIC: no compounds elution during the last 2 minutes of chromatogram
 - ❖ Noise level



MS ANALYSIS

- MS scan: 50-1500 m/z
- MS/MS scan: 50-1400 m/z
- 4 Ions in MS automatically selected for MS/MS by abundance
- Collision energy: 20 eV
- Data storage: Centroid

- 1 Non-fortified controls**
 - ❖ Pooled-urine samples
 - ❖ Solvent Blanks
- 2 MIX-IS fortified controls**
 - ❖ Procedural Blanks
 - ❖ Pooled-urine samples
 - ❖ MIX-IS
- 3 Others controls**
 - ❖ Mass calibration
 - ❖ Duplicate samples
 - ❖ Randomized worklist

DATA-ANALYSIS

- 1 Manual checking – MIX IS**
 - ❖ IS peaks intensities and mass accuracy in all samples
 - ❖ Retention time shifts in samples and controls
 - ❖ Matrix effect for IS in all samples
- 2 Suspect list**
 - ❖ Metabolite prediction
 - ❖ Metabolites phase I & II
 - ❖ MIX-IS
 - ❖ Endogenous compounds
 - ❖ High detection frequency compounds i.e. drugs
- 3 Feature extraction**
 - ❖ Alignment
 - ❖ No Normalisation: high variability of urine composition
 - ❖ No Blank subtraction: ECs are omnipresent compounds
 - ❖ Statistical analysis: Controls must be clustered
- 4 Compound identification**
 - ❖ Mass accuracy 5-10 ppm
 - ❖ Coherence retention time/structure
 - ❖ Isotopic pattern (ions accuracy + relative abundance)
 - ❖ Comparison of MS/MS spectra with databases
 - ❖ Report quality of identification i.e. Schymanski's scale (ES&T 2014, 48(4):2097-8)

Results

- More than 20 ECs were identified at identification levels 2 to 4 according to Schymanski's scale. The achievement of higher levels of identification for many compounds was not possible owing to the lack of MS/MS data available for ECs.
- The highest detection frequencies (DF) are shown in the table:

COMPOUND GROUP	COMPOUND	DF (%)
Benzotriazole metabolite	Hydroperoxide-tolytriazole	100
Phthalate metabolite	Mono-iso-nonyl phthalate	100
Plasticizer	Bisphenol B	95
UV filter metabolite	[hydrox[y2-ethylhexyl 4-(dimethylamino)]benzoate	77

Conclusions

- Although many ECs present in human urine are not yet characterized, a good point to evaluate the whole non-target/suspect screening workflow may be the comparison with the obtained results by other laboratories.
- The establishment of a detailed list of QA/QC measures represents a good starting point for the harmonization of non-target/suspect screening methodologies used in human urine analysis.

Acknowledgements

C. Gys acknowledges a PhD fellowship from the Research Foundation Flanders (FWO) through project G0E5216N. N. Caballero-Casero acknowledges a post-doc fellowship from the University of Antwerp (BOF funds). The authors acknowledge funding from H2020 HBM4EU project (contract 733032).